On October 1, 2019 Ryvu Therapeutics and Selvita (WSE: SLV) reported that the National Court Register of Poland ("KRS") has recognized the corporate split of the Selvita parent company into two distinct organizations (Press release, Ryvu Therapeutics, OCT 1, 2019, View Source [SID1234542463]). The recognition by the court follows the Sept. 19, 2019, shareholder resolution to separate oncology therapeutics and contract research (CRO) business units.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Going forward, Ryvu Therapeutics and Selvita (CRO) will now operate independently with separate executive management teams as well as supervisory boards, in accordance with the shareholder resolution.

Public trading of Ryvu Therapeutics under the symbol RVU, separated from Selvita is expected to begin on or about 9th October, subject to approvals from the National Depository for Securities ("KDPW") and the Warsaw Stock Exchange ("GPW").

Until this time, the value of the two independent companies will be reflected under the current listing of Selvita on the Warsaw Stock exchange.

Public listing of the contract research organization Selvita (CRO) under the symbol SLV is also expected on or about 16th October.